Sichuan Kelun Pharmaceutical Co.,Ltd.: all 65 studies

Page 1 of 1. Open to participants first (40), then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI FailureNot yet recruitingNCT07854509Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KL0011034 Injection Administered by Continuous Infusion in Healthy Adult SubjectsNot yet recruitingNCT07828470Phase 1
• A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic CancerNot yet recruitingNCT07814066Phase 2
• Study of SKB103 in HER2-negative Breast CancerNot yet recruitingNCT07774624Phase 1/2
• A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With AsthmaRecruitingNCT07732023Phase 1
• SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Phase 2
• SKB264 in Combination With SKB118 for Non-Small Cell Lung CancerRecruitingNCT07697586Phase 2
• A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC ParticipantsRecruitingNCT07668154Phase 2
• A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07622186Phase 2
• SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ AdenocarcinomaNot yet recruitingNCT07609667Phase 2
• SKB118 Injection in Advanced Solid TumorsRecruitingNCT07586943Phase 1/2
• A Study of SKB571 in Participants With Gastrointestinal TumorsRecruitingNCT07564466Phase 2
• SKB565 for Injection in Advanced Solid TumorsRecruitingNCT07545265Phase 1/2
• A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis ParticipantsRecruitingNCT07488065Phase 1
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy VolunteersRecruitingNCT07474545Phase 1
• SKB103 for Injection in Advanced Solid TumorsRecruitingNCT07459998Phase 1/2
• A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant TumorsRecruitingNCT07448922Phase 2
• SKB105 for Injection in Advanced Solid TumorsRecruitingNCT07380386Phase 1/2
• Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT07329322Phase 2
• Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaRecruitingNCT07324629Phase 2
• A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET AbnormalitiesRecruitingNCT07308106Phase 2
• A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerRecruitingNCT07299825Phase 2
• SKB500 Combinations in Patients With Small Cell Lung CancerRecruitingNCT07296809Phase 2
• Single-dose,First-in-human of KLA478RecruitingNCT07240675Phase 1
• A Phase II Study of SKB571 in Patients With Lung CancerRecruitingNCT07230405Phase 2
• A Phase I Study of KLA318-2 Nanocrystal InjectionRecruitingNCT07171034Phase 1
• First-in-Human Single and Multiple Dose of KLA578-1 for InjectionRecruitingNCT07143318Phase 1
• A Study of SKB107 in Advanced Solid Tumors With Bone MetastasesRecruitingNCT07087197Phase 1
• A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyRecruitingNCT07071337Phase 3
• A Phase I Clinical Study of a Single Dose of KLA480RecruitingNCT07030790Phase 1
• A Study of SKB518 in Patients With Lung CancerRecruitingNCT07019675Phase 2
• SKB445 for Injection in Solid TumorsRecruitingNCT06826040Phase 1
• A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid TumorsRecruitingNCT06736327Phase 1
• A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid TumorsRecruitingNCT06726369Phase 1
• A Phase 1 Study of SKB571 in Subjects With Advanced Solid TumorsRecruitingNCT06725381Phase 1
• The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.RecruitingNCT06674694Phase 1
• A Study of SKB518 in Patients With Advanced Solid TumorsRecruitingNCT06428331Phase 1
• Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerRecruitingNCT06081959Phase 3
• A Study of SKB315 in Patients With Advanced Solid TumorsRecruitingNCT05367635Phase 1
• SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.RecruitingNCT05351788Phase 2
• A Study Evaluating the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride InjectionCompletedNCT07710560Phase 1
• Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OCActive, not recruitingNCT07341100Phase 2
• A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane TherapyActive, not recruitingNCT06968585Phase 3
• A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06711900Phase 3
• A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06670196Phase 3
• A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06448312Phase 3
• A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06279364Phase 3
• SKB410 for Injection in Solid TumorsCompletedNCT05906537Phase 1
• A Phase III Study of SKB264 for EGFR Mutant NSCLC PatientsActive, not recruitingNCT05870319Phase 3
• SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsActive, not recruitingNCT05631262Phase 2
• A Study of Intratumoral KL340399 in Patients With Advanced Solid TumorsCompletedNCT05549804Phase 1
• A Study of KL130008 in Adults With Severe Alopecia AreataTerminatedNCT05496426Phase 2
• SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerCompletedNCT05445908Phase 2
• A Study of KL340399 in Patients With Advanced Solid TumorsCompletedNCT05387928Phase 1
• SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerActive, not recruitingNCT05347134Phase 3
• A Study of A166 in Patients With Advanced Solid Malignant TumorsCompletedNCT05311397Phase 1
• KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05294172Phase 3
• A Study of KL590586 in Patients With Advanced Solid TumorsActive, not recruitingNCT05265091Phase 1/2
• Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRCCompletedNCT04835142Phase 3
• KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedNCT03848286Phase 2
• An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's LymphomaCompletedNCT03580564Phase 2
• Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody TrialTerminatedNCT03426371Phase 3
• Bioequivalence Study of Gefitinib Tablets Under Fed ConditionsCompletedNCT03050177Phase 1
• Bioequivalence Study of Gefitinib Tablets Under Fasting ConditionsCompletedNCT03050164Phase 1
• Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal CancerCompletedNCT03017807Phase 1

← Sichuan Kelun Pharmaceutical Co.,Ltd. overview and focus areas